StockData
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. (PLX) income statement

PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3047% below fair value
$3.02+0.14 (+4.86%)

Close on Nov 18, 2026Market cap $243.33MP/E 13.1Yield –

Protalix BioTherapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
69.2%
Operating margin
28.9%
Net margin
23.5%
Return on equity, FY2025
-14.4%

Financial strength

Current ratio
2.94
Debt to equity
–
Debt to assets
–
Cash to current liabilities
87.3%

Valuation

P/E ratio
13.1
Price to sales
3.02
Price to book
3.41
Dividend yield
–

See a number that looks wrong?